Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin™

Aplidin™ (APL) is a new antitumoral drug from marine origin currently in phase II clinical trials against a wide multiplicity of cancers. As resistance may be, as with other drugs, an important obstacle to the APL therapeutic efficacy, we have established an acquired resistance cellular model by con...

Descripción completa

Detalles Bibliográficos
Autores principales: Losada, A, López-Oliva, J M, Sánchez-Puelles, J M, García-Fernández, L F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409906/
https://www.ncbi.nlm.nih.gov/pubmed/15365569
http://dx.doi.org/10.1038/sj.bjc.6602166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409906/
https://www.ncbi.nlm.nih.gov/pubmed/15365569
http://dx.doi.org/10.1038/sj.bjc.6602166

Ejemplares similares